legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Barclays PLC Trims Its Stake in Editas Medicine, Inc.

Barclays PLC, a multinational investment bank and financial services company, has reduced its ownership in Editas Medicine, Inc. (NASDAQ: EDIT). According to the company’s recent disclosure with the Securities & Exchange Commission, Barclays PLC sold 165,279 shares, representing a 37.5% decrease in its stake. Following the transaction, Barclays PLC now owns 275,122 shares of Editas Medicine, which is valued at approximately $1,994,000 based on the most recent SEC filing. This stake represents about 0.40% of the company’s total outstanding shares.

This reduction in ownership by Barclays PLC is noteworthy as it indicates a change in the sentiment of institutional investors towards Editas Medicine. It is important for investors to monitor these institutional moves as they can provide insights into the market perception of a company and its future prospects.

Although Barclays PLC has reduced its stake, it is notable that several other hedge funds and institutional investors have made changes to their positions in Editas Medicine. State Street Corp, for example, has increased its stake in Editas Medicine by 43.8% during the second quarter. BlackRock Inc. and Vanguard Group Inc. have also increased their stakes by 3.8% and 3.0% respectively during the previous quarters. These moves indicate a mixed sentiment among institutional investors towards Editas Medicine.

In this situation, AI legalese decoder can help investors make sense of the complex legal language and understand the implications of these institutional moves. By using AI technology, the legalese decoder can quickly analyze and interpret the disclosure documents filed with the SEC, providing investors with a clear understanding of the changes in ownership and potential impact on the company’s stock price.

Analyst Upgrades and Downgrades

Editas Medicine has been the subject of several analyst reports and ratings changes. StockNews.com recently initiated coverage on Editas Medicine, giving it a “sell” rating. Oppenheimer, on the other hand, maintained a “market perform” rating with a price target of $12.00. Raymond James upgraded Editas Medicine from “market perform” to “outperform” and set a price target of $17.00. Chardan Capital lowered their price target from $22.00 to $19.00 but maintained a “buy” rating on Editas Medicine. According to MarketBeat’s data, analysts currently have a consensus rating of “Hold” on Editas Medicine, with an average price target of $15.64.

The AI legalese decoder can assist investors in analyzing these analyst reports and understanding the implications of the ratings on Editas Medicine’s stock. By using AI technology, the Decoder can quickly analyze and summarize the key points of each report, providing investors with valuable insights to make informed investment decisions.

Editas Medicine Stock Performance

Editas Medicine’s stock (NASDAQ: EDIT) opened at $8.48 on Friday. With a market capitalization of $692.25 million, a price-to-earnings ratio of -2.86, and a beta of 1.81, Editas Medicine’s stock has seen its ups and downs. The stock’s 50-day simple moving average is $8.76, and its 200-day simple moving average is $8.80. The stock’s 52-week range is from $6.33 to $16.61.

Understanding the stock’s performance is crucial for investors. The AI legalese decoder can provide investors with historical data and trends, enabling them to better assess Editas Medicine’s stock performance and make more informed investment decisions.

Insider Buying and Selling at Editas Medicine

Recent insider trading activities at Editas Medicine have been disclosed in filings with the Securities & Exchange Commission. CEO Gilmore Neil O’neill sold 6,486 shares of the company’s stock at an average price of $9.50, totaling $61,617.00. Additionally, SVP Baisong Mei sold 4,317 shares at an average price of $8.80, amounting to $37,989.60. It is important for investors to consider insider buying and selling activities when assessing a company, as they can provide insights into the company’s future performance and management’s confidence in the business.

The AI legalese decoder can help investors analyze and understand these insider transactions, providing insights into the significance of these actions and their potential impact on the company’s stock price.

Editas Medicine Company Profile

Editas Medicine, Inc. is a clinical-stage genome editing company focused on developing transformative genomic medicines to treat various serious diseases. The company utilizes its proprietary gene editing platform based on CRISPR technology. Editas Medicine has multiple drug candidates in various stages of development, including EDIT-101 for Leber Congenital Amaurosis 10 and autosomal dominant retinitis pigmentosa, and EDIT-301 for sickle cell disease and transfusion-dependent beta-thalassemia.

The AI legalese decoder can provide investors with a detailed evaluation of Editas Medicine’s company profile, including its key therapeutic candidates, clinical trials, and potential market opportunities. This information can assist investors in assessing the company’s growth prospects and making well-informed investment decisions.

Recommended Stories

MarketBeat’s editorial team has reviewed this news alert, which was generated by narrative science technology and financial data from MarketBeat. For any questions or comments about this story, please contact [email protected].

Before making any investment decisions regarding Editas Medicine, investors may want to consider the insights provided by MarketBeat’s top-rated and best-performing research analysts. These analysts have identified five stocks that they quietly recommend to their clients as better buys than Editas Medicine. To learn more about these stocks and their potential, please view the article on MarketBeat’s website.

legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Reference link